Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy
This article was originally published in Scrip
Executive Summary
UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.